The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 14, 2021

Filed:

Jan. 18, 2018
Applicant:

Medtronic Minimed, Inc., Northridge, CA (US);

Inventors:

Kiem H. Dang, Thousand Oaks, CA (US);

Sarnath Chattaraj, Simi Valley, CA (US);

Hsi C. Fusselman, Simi Valley, CA (US);

Lance P. Hoffman, West Hollywood, CA (US);

Guangping Zhang, Calabasas, CA (US);

Assignee:

Medtronic MiniMed, Inc., Northridge, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61L 29/14 (2006.01); A61K 38/28 (2006.01); A61K 31/727 (2006.01); A61L 29/04 (2006.01); A61M 5/142 (2006.01); A61M 5/38 (2006.01); A61K 9/00 (2006.01); A61M 39/10 (2006.01); A61M 39/16 (2006.01); A61M 5/158 (2006.01);
U.S. Cl.
CPC ...
A61L 29/146 (2013.01); A61K 9/0019 (2013.01); A61K 31/727 (2013.01); A61K 38/28 (2013.01); A61L 29/049 (2013.01); A61M 5/142 (2013.01); A61M 5/14248 (2013.01); A61M 5/14276 (2013.01); A61M 5/38 (2013.01); A61M 39/10 (2013.01); A61M 39/162 (2013.01); A61M 5/158 (2013.01); A61M 2005/1586 (2013.01); A61M 2205/0272 (2013.01); A61M 2205/3334 (2013.01); A61M 2205/584 (2013.01); A61M 2205/7545 (2013.01); A61M 2207/00 (2013.01); A61M 2230/201 (2013.01);
Abstract

This invention pertains to systems and components useful for infusing medications such as insulin. Typically, the components are used to deliver insulin to a diabetic patient at a site of infusion over a period of time greater than 4 days. The system components typically comprise a cannula adapted for subcutaneous insertion into a diabetic patient. The system further comprises a fluid conduit adapted to deliver the insulin solution from a medication reservoir to the site of infusion and a depot in operable contact with the fluid conduit. The depot comprises selected materials including a site-loss mitigating agent (such as heparin) which inhibits inflammation at the site of infusion, and encapsulation of the cannula at the site of infusion. The site-loss mitigating agent is not premixed with the insulin, and instead is adapted to contact the insulin solution in the depot as the insulin solution flows from the medication reservoir to the site of infusion.


Find Patent Forward Citations

Loading…